Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Endocrinol Invest ; 45(9): 1719-1727, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35579861

ABSTRACT

PURPOSE: To assess the prevalence of pre-diabetes phenotypes, i.e., impaired fasting glucose (IFG), impaired glucose tolerance (IGT), increased HbA1c (IA1c), and their association with metabolic profile and atherogenic lipid profile in youths with overweight/obesity (OW/OB). METHODS: This cross-sectional study analyzed data of 1549 youths (5-18 years) with OW/OB followed in nine Italian centers between 2016 and 2020. Fasting and post-load measurements of glucose, insulin, and HbA1c were available. Insulin resistance (IR) was estimated by HOMA-IR and insulin sensitivity (IS) by reciprocal of fasting insulin. The atherogenic lipid profile was assessed by triglycerides-to-HDL ratio or cholesterol-to-HDL ratio. Insulinogenic index was available in 939 youths, in whom the disposition index was calculated. RESULTS: The prevalence of overall pre-diabetes, IFG, IGT and IA1c was 27.6%, 10.2%, 8% and 16.3%, respectively. Analyzing each isolated phenotype, IGT exhibited two- to three-fold higher odds ratio of family history of diabetes, and worse metabolic and atherogenic lipid profile vs normoglycemic youths; IFG was associated only with IR, while IA1c showed a metabolic and atherogenic lipid profile intermediate between IGT and IFG. CONCLUSION: Prevalence of pre-diabetes was high and IA1c was the most prevalent phenotype in Italian youths with OW/OB. The IGT phenotype showed the worst metabolic and atherogenic lipid profile, followed by IA1c. More studies are needed to assess whether HbA1c may help improving the prediction of diabetes.


Subject(s)
Glucose Intolerance , Insulin Resistance , Prediabetic State , Blood Glucose/metabolism , Cross-Sectional Studies , Fasting , Glucose Intolerance/epidemiology , Glucose Tolerance Test , Glycated Hemoglobin/analysis , Humans , Insulin , Obesity/epidemiology , Overweight/epidemiology , Phenotype , Prediabetic State/epidemiology
2.
J Endocrinol Invest ; 44(6): 1275-1281, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32960416

ABSTRACT

PURPOSE: The main aim of the study was to assess the relationship between leptin, ghrelin, insulin-like growth factor 1 (IGF-1), and glucagon-like peptide 1 (GLP-1) blood levels and gastric motility in children with obesity compared to healthy children. Secondary aims were to assess the possible association between these hormones and obesity, reflux impedance parameters, reflux symptoms, other GI disorders, and quality-of-life scores within the same groups. METHODS: Children with obesity plus GERD symptoms and 2 control groups of children with obesity without GERD and healthy lean children aged 4-17 years underwent an auxological evaluation, an assessment of gastro-intestinal symptoms and quality of life, hormonal dosages, and an evaluation of gastric emptying time (GET) through 13C-octanoic acid breath test. RESULTS: No significant association was found between hormones and gastric motility. Leptin and ghrelin levels were significantly associated with obesity parameters. No significant differences were found between GET and hormones of the patients with obesity, either with or without GERD. CONCLUSION: Although we found an association between auxological parameters and both leptin and ghrelin levels, this association did not imply an effect on the upper GI motility. Therefore, our hypothesis that alterations of these hormones in children with obesity could affect gastric emptying, triggering GERD, was not supported by our data.


Subject(s)
Esophageal pH Monitoring , Gastric Emptying/physiology , Ghrelin/blood , Glucagon-Like Peptide 1/blood , Insulin-Like Growth Factor I/analysis , Leptin/blood , Obesity , Quality of Life , Child , Correlation of Data , Esophageal pH Monitoring/methods , Esophageal pH Monitoring/statistics & numerical data , Female , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/etiology , Gastrointestinal Diseases/diagnosis , Gastrointestinal Diseases/etiology , Humans , Male , Obesity/blood , Obesity/diagnosis , Obesity/physiopathology , Obesity/psychology
3.
Acta Diabetol ; 55(12): 1247-1250, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30105470

ABSTRACT

AIMS: Many authors do not recommend hypoglycemic treatment during pregnancy in women affected by monogenic diabetes due to heterozygous glucokinase (GCK) mutations (MODY 2) in case of affected fetus, because maternal hyperglycemia would be necessary to achieve a normal birthweight. We aimed to evaluate differences in birthweight between MODY 2 affected children according to the parent who carried the mutation. METHODS: We retrospectively studied 48 MODY 2 affected children, whose mothers did not receive hypoglycemic treatment during pregnancy, divided into two groups according to the presence of the mutation in the mother (group A) or in the father (group B). Data were extracted from the database of the Regional Centre of Pediatric Diabetology of the University of Campania, Naples, collected from 1996 to 2016. We analyzed birthweight and centile birthweight. RESULTS: Percentage of small for gestational age was significantly higher in group B than in group A. We found three large for gestational age in the group that inherited the deficit from the mother, all with the same novel GCK mutation (p.Lys458-Cys461del). CONCLUSIONS: We hypothesize that not all MODY 2 affected fetuses need the same levels of hyperglycemia to have an appropriate growth, maybe because different kinds of GCK mutations may result in different phenotypes. Consequently, a "tailored therapy" of maternal hyperglycemia, based on fetal growth frequently monitored through ultrasounds, is essential in MODY 2 pregnancies.


Subject(s)
Birth Weight/genetics , Diabetes Mellitus, Type 2/genetics , Fetal Development , Glucokinase/genetics , Hyperglycemia , Mutation , Pregnancy in Diabetics , Adult , Child , Child, Preschool , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Female , Fetal Development/genetics , Fetus/metabolism , Gestational Age , Humans , Hyperglycemia/blood , Hyperglycemia/drug therapy , Hyperglycemia/genetics , Hypoglycemic Agents/therapeutic use , Infant, Newborn , Male , Mothers , Phenotype , Pregnancy , Pregnancy in Diabetics/blood , Pregnancy in Diabetics/drug therapy , Pregnancy in Diabetics/genetics , Prenatal Exposure Delayed Effects/blood , Prenatal Exposure Delayed Effects/genetics , Prenatal Exposure Delayed Effects/metabolism , Retrospective Studies
4.
Acta Diabetol ; 52(4): 633-8, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25863781

ABSTRACT

Diabetes mellitus is the most common comorbidity in cystic fibrosis (CF), occurring in a variable number of children and adolescents. Glucose metabolism derangements (GMDs) are responsible for a negative impact on the general health status of CF patients. Screening of GMDs is important since the youngest age and should be performed by means of OGTT, including its intermediate times, that could detect other non-traditional GMDs. Insulin treatment, administered before overt diabetes, could be beneficial in reducing the number of pulmonary infections, in improving both pulmonary function and nutritional status. Early screening of GMDs in pediatric age can exert an important preventing role regarding all aspects of health status of patients with CF.


Subject(s)
Cystic Fibrosis/metabolism , Glucose Intolerance/diagnosis , Mass Screening/statistics & numerical data , Adolescent , Child , Child, Preschool , Comorbidity , Cystic Fibrosis/complications , Cystic Fibrosis/diagnosis , Cystic Fibrosis/epidemiology , Diabetes Complications/blood , Diabetes Complications/epidemiology , Diabetes Mellitus/blood , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Glucose Intolerance/blood , Glucose Intolerance/epidemiology , Glucose Tolerance Test , Humans
5.
Minerva Pediatr ; 64(4): 413-31, 2012 Aug.
Article in Italian | MEDLINE | ID: mdl-22728613

ABSTRACT

Obesity is a complex public health issue. Recent data indicate the increasing prevalence and severity of obesity in children. Severe obesity is a real chronic condition for the difficulties of long-term clinical treatment, the high drop-out rate, the large burden of health and psychological problems and the high probability of persistence in adulthood. A staged approach for weight management is recommended. The establishment of permanent healthy lifestyle habits aimed at healthy eating, increasing physical activity and reducing sedentary behavior is the first outcome, because of the long-term health benefits of these behaviors. Improvement in medical conditions is also an important sign of long-term health benefits. Rapid weight loss is not pursued, for the implications on growth ad pubertal development and the risk of inducing eating disorders. Children and adolescents with severe obesity should be referred to a pediatric weight management center that has access to a multidisciplinary team with expertise in childhood obesity. This article provides pediatricians a comprehensive and evidence based update on treatment recommendations of severe obesity in children and adolescents.


Subject(s)
Behavior Therapy , Diet, Reducing , Exercise , Obesity, Morbid/therapy , Weight Loss , Adolescent , Behavior Therapy/methods , Body Mass Index , Child , Evidence-Based Medicine , Humans , Italy/epidemiology , Life Style , Obesity, Morbid/diagnosis , Obesity, Morbid/epidemiology , Prevalence , Severity of Illness Index , Treatment Outcome
6.
Horm Res ; 58(6): 266-72, 2002.
Article in English | MEDLINE | ID: mdl-12446989

ABSTRACT

AIM: To analyze whether bone mineral density (BMD) and bone resorption status are influenced by long-term metabolic control and duration of disease in adolescents with long-standing type 1 diabetes mellitus. METHODS: Twenty-seven adolescents (age 13.1 +/- 1.7 years, duration of diabetes 6.9 +/- 3.0 years) were studied. The BMD, expressed as z score, was measured at the lumbar spine (L1-L4) using dual-energy X-ray absorptiometry, while the urinary excretion of total deoxypiridinoline (Dpyd), a marker of bone resorption, was measured by immunoassay and was corrected by creatinine (Cr). Linear and multivariate correlations between lumbar BMD z score or Dpyd/Cr excretion and age and disease variables [short-term (Hb A(1c latest)) or long-term (Hb A(1c whole duration)) metabolic control, duration, 'diabetes impact index' (mean Hb A(1c whole duration) x duration of disease in months)] were sought. RESULTS: In diabetic subjects the mean BMD z score was -0.44 +/- (SD) 1.02 (95% CI: -0.03; -0.84), and the Dpyd/Cr excretion was not increased. A negative correlation was found between lumbar BMD z score and age (r -0.59; p = 0.001), duration (r -0.39; p = 0.04), and the diabetes impact index (r -0.4; p = 0.04). The Dpyd/Cr ratio correlated negatively with age (r -0.40; p = 0.04) and positively with height velocity (r 0.42; p = 0.04). By using multiple linear regression, age showed a significant inverse correlation with lumbar BMD z score (beta = -0.39; p = 0.0005). A negative correlation was found between lumbar BMD z score and Hb A(1c whole duration) (beta = -0.40; p = 0.02) or diabetes impact index (beta = -0.001; p = 0.01). CONCLUSIONS: Poor metabolic control may expose adolescents with long-standing type 1 diabetes to the risk of developing osteopenia in adult age. Optimization of metabolic control in growing diabetic children may prevent osteoporosis in later life.


Subject(s)
Blood Glucose/metabolism , Bone Density/physiology , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/metabolism , Spine/pathology , Absorptiometry, Photon , Adolescent , Biomarkers , Body Height , Body Weight , Bone Resorption/etiology , Bone Resorption/urine , Child , Diabetes Mellitus, Type 1/pathology , Female , Glycated Hemoglobin/metabolism , Humans , Male , Pyridinium Compounds/urine , Spine/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL